poisar

Stocks · News reference

8-K filing — ANAVEX LIFE SCIENCES CORP. (AVXL)

SEC EDGAR

Filed: 2026-09-02 AccNo: 0001731122-26-001179 Size: 208 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

AVXL
Source
edgar
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Pvg Asset Management Corporation

    PVG Sends Open Letter to Anavex Stockholders Detailing the Need for Change at the Company

    PVG Asset Management, a significant shareholder of Anavex Life Sciences, has launched a proxy contest calling for complete board reconstitution, citing operational failures, governance issues, and failure to deliver shareholder value. PVG has nominated six biotechnology-experienced directors to replace the current board, criticizing the company's underperformance relative to peers, delayed clinical trials for its lead drug blarcamesine, significant executive departures, and recent stock decline amid broader biotech sector gains.

    AVXLAXSMXBI
  2. Anavex Life Sciences Corp.

    Anavex Life Sciences Regains Compliance with Nasdaq Periodic Filing Requirement

    Anavex Life Sciences announced it has regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing outstanding Form 10-Q filings for Q2 and Q3 2026 on August 28, 2026. The clinical-stage biopharmaceutical company, focused on CNS disease treatments, continues to advance its three core clinical development programs with emphasis on Alzheimer's disease.

    AVXL
  3. Benzinga Newsdesk

    Anavex Life Sciences Regains Nasdaq Compliance

    Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system ("CNS")

    AVXL